Dr. Reddy's Laboratories is currently trading at Rs. 3137.05, up by 14.40 points or 0.46% from its previous closing of Rs. 3122.65 on the BSE.
The scrip opened at Rs. 3123.00 and has touched a high and low of Rs. 3142.85 and Rs. 3123.00 respectively.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.
Last one week high and low of the scrip stood at Rs. 3142.85 and Rs. 3019.00 respectively. The current market cap of the company is Rs. 51,959.00 crore.
The promoters holding in the company stood at 26.37%, while Institutions and Non-Institutions held 41.16% and 15.64% respectively.
Dr. Reddy's Laboratories has launched Bupropion HCI extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR (bupropion HCI) Sustained-Release Tablets in the United States market approved by the US Food & Drug Administration (USFDA). Dr. Reddy's Buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.
Wellbutrin SR is a registered trademark of the GSK group of companies. The Wellbutrin SR brand and generic had US sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016, according to IMS Health.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It is committed to provide affordable and innovative medicines for healthier lives. It manufactures and markets a wide range of pharmaceuticals in India and overseas.